Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy

被引:8
|
作者
Lin, Baiqiang [3 ]
Zhao, Fuya [3 ,6 ]
Liu, Yang [1 ,2 ,3 ]
Sun, Jiayu [3 ,7 ]
Feng, Jing [3 ]
Zhao, Lei [3 ]
Wang, Haoran [3 ]
Chen, Hongye [3 ]
Yan, Wei [3 ]
Guo, Xiao [3 ]
Shi, Shang [3 ]
Li, Zhiyong [3 ]
Wang, Shuang [3 ]
Lu, Yu [3 ]
Zheng, Jianjun [4 ,5 ]
Wei, Yunwei [1 ,2 ,3 ]
机构
[1] Univ Chinese Acad Sci, HwaMei Hosp, Pancreat & Gastrointestinal Surg Div, Ningbo, Peoples R China
[2] Ningbo Clin Res Ctr Digest Syst Tumors, Ningbo, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 1, Oncol & Laparoscopy Surg, Harbin, Peoples R China
[4] Univ Chinese Acad Sci, HwaMei Hosp, Imaging Ctr, Ningbo, Peoples R China
[5] Ningbo Clin Med Res Ctr Imaging Med, Ningbo, Peoples R China
[6] Fujian Med Univ, Affiliated Hosp 1, Gastrointestinal Surg, Fuzhou, Peoples R China
[7] SouthernMed Univ, Zhujiang Hosp, Gen Surg, Guangzhou, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
oral microbiota; xerostomia; differentiated thyroid carcinoma; radioiodine therapy; 16S rRNA; SALIVARY-GLAND FUNCTION; RADIOACTIVE IODINE; CANCER; INFLAMMATION; LIPOPOLYSACCHARIDE; RADIATION; CAVITY;
D O I
10.3389/fendo.2022.895970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and AimsOral xerostomia remains one of the most common complications of differentiated thyroid carcinoma patients (DTC) after radioiodine therapy (RAI). Environmental factors in the etiology of xerostomia are largely unknown. We aimed to characterize the oral microbiota signatures and related biological functions associated with xerostomia and identify environmental factors affecting them. MethodsSaliva was collected from 30 DTC patients with xerostomia (XAs), 32 patients without xerostomia (indicated as non-XAs) following RAI after total thyroidectomy, and 40 healthy people (HCs) for 16S rRNA sequencing analysis. ResultsThe oral microbiota of XAs and non-XAs exhibited significant differences in alpha and beta diversities and bacterial taxa. The abundance of porphyromonas, fusobacterium, and treponema_2 were significantly higher in XAs, while the abundance of the streptococcus was lower in the microbiota of non-XAs. Fusobacterium, and porphyromonas were negatively correlated with unstimulated/stimulated whole salivary secretion (USW)/(SWS), while fusobacterium, porphyromonas, and treponema_2 genera levels were positively associated with cumulative radioiodine dose. PICRUSt2 and BugBase suggested a significant difference in the expression of potentially_pathogenic, anaerobic, gram_negative, the arachidonic acid metabolism, and lipopolysaccharide (LPS) biosynthesis between XAs and non-XAs, possibly interdependent on radioiodine-induced inflammation. NetShift analysis revealed that porphyromonas genus might play as a key driver during the process of xerostomia. Five genera effectively distinguished XAs from non-XAs (AUC = 0.87). ConclusionOur study suggests for the first time that DTC patients with xerostomia after RAI display microbiota profiles and associated functional changes that may promote a pro-inflammatory environment. Dysbiosis of the oral microbiota may contribute to exacerbating the severity of xerostomia. Our results provide a research direction of the interaction mechanism between oral microbiota alteration and the progress of xerostomia.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] SYNTHESIS OF THYROGLOBULIN IN THYROID-CARCINOMA PATIENTS AFTER RADIOIODINE THERAPY
    JEEVANRAM, RK
    SHAH, DH
    KUMAR, BSA
    SHARMA, SM
    GANATRA, RD
    CANCER, 1983, 52 (12) : 2240 - 2244
  • [32] OUTCOME AFTER HIGH-DOSE RADIOIODINE THERAPY FOR ADVANCED DIFFERENTIATED THYROID CARCINOMA IN CHILDHOOD
    Gao, Yun-Chao
    Lu, Han-Kui
    ENDOCRINE RESEARCH, 2009, 34 (04) : 121 - 129
  • [33] Guidelines on radioiodine therapy for differentiated thyroid carcinoma -: Impact on clinical practice
    Biermann, M
    Pixberg, MK
    Dörr, U
    Dietlein, M
    Schlemmer, H
    Grimm, J
    Zajic, T
    Nestle, U
    Ladner, S
    Sepehr-Rezai, S
    Rosenbaum, S
    Puskás, C
    Fostitsch, P
    Heinecke, A
    Schuck, A
    Willich, N
    Schmid, KW
    Dralle, H
    Schober, O
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2005, 44 (06): : 229 - +
  • [34] ''High-dose'' radioiodine therapy in advanced differentiated thyroid carcinoma
    Menzel, C
    Grunwald, F
    Schomburg, A
    Palmedo, H
    Bender, H
    Spath, G
    Biersack, HJ
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (09) : 1496 - 1503
  • [35] RADIOIODINE THERAPY IN WELL-DIFFERENTIATED PAPILLARY AND FOLLICULAR CARCINOMA OF THYROID
    VARMA, VM
    REBA, RC
    JOURNAL OF NUCLEAR MEDICINE, 1978, 19 (06) : 714 - 715
  • [36] Editorial: Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma
    Sherman, SI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09): : 4059 - 4062
  • [37] RADIOIODINE THERAPY IN DIFFERENTIATED THYROID-CARCINOMA IN CHILDHOOD - A RETROSPECTIVE STUDY
    DOTTORINI, ME
    MAZZUCCHELLI, L
    LOMUSCIO, G
    VIGNATI, A
    COLOMBO, L
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (05) : P226 - P227
  • [38] Carotid artery rupture following radioiodine therapy for differentiated thyroid carcinoma
    Cunha, Danilo da Silva
    Previato Simoes, Maria Izilda
    Viviani, Dionsio Nepomuceno
    Boldrini, Domingos
    da Rocha, Euclides Timoteo
    Morini, Sandra Regina
    Moriguchi, Sonia Marta
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2011, 55 (06) : 419 - 425
  • [39] Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy
    Haq, MS
    McCready, RV
    Harmer, CL
    NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (08) : 799 - 805
  • [40] Radioiodine therapy cumulative doses in differentiated thyroid carcinoma: When to stop?
    Filho, R. M.
    Santos, A. O.
    Amorim, B. J.
    Lima, M. C. L.
    Ramos, C. D.
    Aguiar, T.
    Lima, M. C. V. L.
    Matos, P. S.
    Ward, L.
    Assumpcao, L. V. M.
    Etchebehere, E. C. S. C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S215 - S215